ID: MRFR/Pharma/3554-HCR | 85 Pages | Published By Rahul Gotadki on March 2023
Anoxia Market Scenario
Anoxia is a condition that occurs due to complete loss of oxygen in body or brain which leads to various cognitive problems, and disabilities. It is considered as a severe cause of hypoxia. The most common causes of anoxia are respiratory arrest, drowning, carbon monoxide inhalation, illegal drug use, brain tumors, heart arrhythmia, suffocation, compression of the trachea, heart attack, and many others. Anoxic brain injury is also known as hypoxic-anoxic injury (HAI) or cerebral hypoxia. There are different types of anoxia, and each has an internal, and external causes. For instance, anemic anoxia occurs when blood is unable to carry enough oxygen to keep organs functioning properly, whereas, stagnant anoxia occurs when blood doesn’t reach brain or other body parts properly. Cardiovascular events such as, heart attack, cardiac arrhythmia, heart failure, and stroke, are the most common causes of stagnant anoxia. Anoxic anoxia usually at high altitudes. According to a study published in the Neural Regeneration Research journal, it is found that the with the increasing altitude partial pressure of oxygen falls which results in anoxic challenge to the person ascending to high altitudes.
Short-term memory loss, poor performance in executive functions, anomia, and visual disturbances are the commonly known cognitive problems associated with anoxia, whereas, physical problems include ataxia (lack of coordination), apraxia (inability to do common tasks), movement disorders, quadriparesis, and headaches.
Notably, rising cases of cardiac arrest is the key factor driving the anoxia market. According to a study published in the Critical Care journal in 2017, it is found that hypoxic ischemic brain injury (HIBI) is an outcome of cardiac arrest. It is stated that HIBI is the major cause of death in 23% of out-of-hospital cardiac arrest, and in 68% of inpatient cardiac arrest.
Various other factors such as, increasing awareness among people, increasing government assistance, and improvement in regulatory framework continuously contribute to the growth of the global anoxia market.
Despite these drivers, there are some issues associated with anoxia market. Challenges in research and development, and poor healthcare system in low and middle income countries may hinder the growth of market to an extent.
It is estimated that anoxia market is expected to grow at a CAGR 5.4% during the forecast period of 2017-2023.
The anoxia market is segmented on the basis of type, diagnosis, treatment, and end-user.
On the basis of type, market is segmented into anemic anoxia, toxic anoxia, stagnant anoxia, and anoxic anoxia.
On the basis of diagnosis, market is classified into blood tests, MRI (magnetic resonance imaging), CT or CAT scan (computerized axial tomography), evoked potential tests, and EEG (electroencephalogram).
On the basis of treatment, market is classified into cardiopulmonary resuscitation (CPR), rehabilitation therapies, and medication. Rehabilitation therapies is further segmented into speech therapy physical therapy, occupational therapy, recreational therapy, and adaptive equipment training. Medication is also further classified into ammonia reducer, anticonvulsant, steroids, vitamin, and others.
On the basis of end-users, market is segmented into hospital & clinics, diagnostic centers, research institutes, rehabilitation Centers, and others.
The Americas dominate the anoxia market owing to the rise in awareness among people, and high healthcare expenditure. According to the Centers for Disease Control and Prevention, in 2015, the total health expenditure in the United States was reported to be USD 3.2 trillion and hospital care accounted for a share of 32.3%.
Europe holds the second position in anoxia market. It is expected that the support provided by government bodies for research & development and improvement in reimbursement policies in healthcare will drive the market in Europe region.
Asia Pacific is the fastest growing anoxia market owing to the huge patient pool and developing healthcare technology. Healthcare expenditure is also improving in various Asia Pacific countries. According to the Australian Institute of Health and Welfare, in the years 2015 to 2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than expenditure of 2014–15.
The Middle East & Africa has the lowest Anoxia Market due to lack of technical knowledge and poor medical facilities.
Some of key the players in the anoxia market are Pfizer, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc,, Cephalon Inc., Shire, UCB S.A, and others.
Sources: Annual reports, Press release, White paper, and Company presentation
anoxia market CAGR would be 5.4% during the forecast period.
anoxia market would get bogged down by lack of investment in research & development, and poor healthcare system in various low income countries.
anoxia market would be dominated by the Americas.
The players mentioned in the anoxia market Abbott Laboratories, Pfizer, GlaxoSmithKline plc, Novartis AG, Shire, UCB S.A, Cephalon Inc., and others.
The Asia Pacific anoxia market is the fastest-growing region.